硬化療法の世界市場2020-2027:薬品別(洗剤、化学刺激剤、浸透剤)、種類別(超音波、液体、泡)、地域別

◆英語タイトル:Sclerotherapy Market Size, Share & Trends Analysis Report By Agent (Detergents, Chemical Irritants, Osmotic Agents), By Type (Ultrasound, Liquid, Foam), By Region, And Segment Forecasts, 2020 - 2027
◆商品コード:GV20SP0159
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2020年8月31日
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥642,600見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥750,600見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥966,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Grand View Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは硬化療法の世界市場について詳細に調査・分析し、調査手法・範囲、エグゼクティブサマリー、市場定義、市場要因・動向・範囲、エージェント見通し、種類別(超音波硬化療法、液体硬化療法、フォーム硬化療法)分析、地域別分析、競争状況などを掲載しています。
・調査手法・範囲
・エグゼクティブサマリー
・市場定義
・市場要因・動向・範囲
・エージェント見通し
・硬化療法の世界市場規模:種類別(超音波硬化療法、液体硬化療法、フォーム硬化療法)
・硬化療法の世界市場規模:地域別
・競争状況
【レポートの概要】

Sclerotherapy Market Growth & Trends

The global sclerotherapy market size is expected to reach USD 1.3 billion by 2027, expanding at a CAGR of 5.6%, according to a new report by Grand View Research, Inc. Sclerotherapy is a non-invasive procedure that is widely used as a primary treatment for reticular veins, leg telangiectasias, and varicose veins. The procedure comprises injecting a solution (sclerosing agents or sclerosants) straight into the affected veins, which causes them to shrink and eventually disappear and assist in treating related symptoms such as aching, burning, swelling, and cramping. Factors like the better exposure to the site of application, utilization of less-invasive technologies, advances in dermatology, and increasing geriatric population with an incidence of varicose veins are fuelling the market growth.

Sclerosing agents used for the treatment of varicose veins are segmented into detergents, hyperosmolar/ osmotic agents, and chemical irritants. Agents like Sodium tetradecyl sulfate (Sotradecol) and Polidocanol (Asclera), Sodium morrhuate (Scleromate), Ethanolamine Oleate (Ethamoline) are all FDA approved sclerosants used to treat and reduce the effect of vein damage. According to the Society of Vascular surgery, more than 33.0% of women and about 17.0% of men consult a doctor for telangiectasias and varicose veins in industrialized countries, affecting up to 35.0% of people in the U.S. alone.

This condition, if left untreated can cause severe health problems such as chronic pain, deep vein clots, skin ulcers, and coronary ailments. According to NCBI, 20.0% of all adults will get varicose veins at some point in their lives and the prevalence is higher among the aging population and women. These factors are expected to boost the market growth. However, the side effects of this procedure such as hyperpigmentation and matting, scarring, and allergic reactions in some patients might hinder the market growth.

Sclerotherapy Market Report Highlights

• The detergent segment emerged as the largest segment in 2019 owing to high approvals by the FDA, low risk of clot formation, effectiveness, and its popularity among doctors

• The foam sclerotherapy segment is anticipated to grow fast over the forecast period due to better exposure to the onsite and results than liquid sclerotherapy

• North America dominated the market in 2019 owing to increasing demand for new technologies, a large pool of key players, rising prevalence of varicose veins, and advanced healthcare infrastructure in the region

• Asia Pacific is expected to reciprocate the highest CAGR over the forecast period.

【レポートの目次】

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market segmentation & scope
1.2. Information procurement
1.2.1. Purchased database
1.2.2. GVR’s internal database
1.2.3. Secondary sources & third-party perspectives
1.2.4. Primary research
1.3. Information analysis
1.3.1. Data analysis models
1.4. Market formulation & data visualization
1.5. Data validation & publishing
Chapter 2. Executive Summary
Chapter 3. Market Definitions
Chapter 4. Sclerotherapy Market Variables, Trends & Scope
4.1. Market Size and Growth Prospects
4.2. Industry Value Chain Analysis
4.3. Market Dynamics
4.3.1. Market Driver Analysis
4.3.1.1. Increasing Geriatric Population with Incidence of Varicose Veins
4.3.1.2. Increase of Technological Advancements Pertaining to Venous Diseases
4.3.1.3. Increasing Demand of Less Invasive Procedures
4.3.2. Market Restraint/ Challenges Analysis
4.3.2.1. Side effects and Risks associated with Sclerotherapy treatment
4.4. Penetration & Growth Prospect Mapping
4.5. Business Environment Analysis Tools
4.5.1. Industry Analysis – Porter’s
4.5.2. PEST Analysis
4.6. Company Market Share Analysis, 2019
Chapter 5. Sclerotherapy Market Agent Outlook
5.1. Sclerotherapy Market: Market Share Analysis, 2019 & 2027
5.1.1. Detergents
5.1.1.1. Detergents Market, 2016 – 2027 (Usd Million)
5.1.2. Chemical Agents
5.1.2.1. Chemical Agents Market, 2016 – 2027 (Usd Million)
5.1.3. Osmotic Agents
5.1.3.1. Osmotic Agents Market, 2016 – 2027 (Usd Million)
Chapter 6. Sclerotherapy Market Type Outlook
6.1. Sclerotherapy Market: Market Share Analysis, 2019 & 2027
6.1.1. Ultrasound Sclerotherapy
6.1.1.1. Ultrasound Sclerotherapy Market, 2016 – 2027 (Usd Million)
6.1.2. Liquid Sclerotherapy
6.1.2.1. Liquid Sclerotherapy Market, 2016 – 2027 (Usd Million)
6.1.3. Foam Sclerotherapy
6.1.3.1. Foam Sclerotherapy Market, 2016 – 2027 (Usd Million)
Chapter 7. Sclerotherapy Regional Outlook
7.1. Sclerotherapy Market, By Region, 2019 & 2027
7.2. North America
7.2.1. Market estimates and forecasts by Agent, 2016 – 2027 (Revenue, USD Million)
7.2.2. Market estimates and forecasts by Type, 2016 – 2027 (Revenue, USD Million)
7.2.3. The U.S.
7.2.3.1. Market estimates and forecasts by Agent, 2016 – 2027 (Revenue, USD Million)
7.2.3.2. Market estimates and forecasts by Type, 2016 – 2027 (Revenue, USD Million)
7.2.4. Canada
7.2.4.1. Market estimates and forecasts by Agent, 2016 – 2027 (Revenue, USD Million)
7.2.4.2. Market estimates and forecasts by Type, 2016 – 2027 (Revenue, USD Million)
7.3. Europe
7.3.1. Market estimates and forecasts by Agent, 2016 – 2027 (Revenue, USD Million)
7.3.2. Market estimates and forecasts by Type, 2016 – 2027 (Revenue, USD Million)
7.3.3. Germany
7.3.3.1. Market estimates and forecasts by Agent, 2016 – 2027 (Revenue, USD Million)
7.3.3.2. Market estimates and forecasts by Type, 2016 – 2027 (Revenue, USD Million)
7.3.4. The U.K.
7.3.4.1. Market estimates and forecasts by Agent, 2016 – 2027 (Revenue, USD Million)
7.3.4.2. Market estimates and forecasts by Type, 2016 – 2027 (Revenue, USD Million)
7.3.5. France
7.3.6.1 Market estimates and forecasts by Agent, 2016 – 2027 (Revenue, USD Million)
7.3.6.2 Market estimates and forecasts by Type, 2016 – 2027 (Revenue, USD Million)
7.3.6. Italy
7.3.7.1Market estimates and forecasts by Agent, 2016 – 2027 (Revenue, USD Million)
7.3.7.2 Market estimates and forecasts by Type, 2016 – 2027 (Revenue, USD Million)
7.3.7. Spain
7.3.8.1 Market estimates and forecasts by Agent, 2016 – 2027 (Revenue, USD Million)
7.3.8.2Market estimates and forecasts by Type, 2016 – 202 (Revenue, USD Million)
7.4. Asia Pacific
7.4.1. Market estimates and forecasts by Agent, 2016 – 2027 (Revenue, USD Million)
7.4.2. Market estimates and forecasts by Type, 2016 – 2027 (Revenue, USD Million)
7.4.3. China
7.4.3.1. Market estimates and forecasts by Agent, 2016 – 2027 (Revenue, USD Million)
7.4.3.2. Market estimates and forecasts by Type, 2016 – 2027 (Revenue, USD Million)
7.4.4. India
7.4.4.1. Market estimates and forecasts by Agent, 2016 – 2027 (Revenue, USD Million)
7.4.4.2. Market estimates and forecasts by Type, 2016 – 2027 (Revenue, USD Million)
7.4.5. Japan
7.4.5.1. Market estimates and forecasts by Agent, 2016 – 2027 (Revenue, USD Million)
7.4.5.2. Market estimates and forecasts by Type, 2016 – 2027 (Revenue, USD Million)
7.4.6. Australia
7.4.6.1. Market estimates and forecasts by Agent, 2016 – 2027 (Revenue, USD Million)
7.4.6.2 Market estimates and forecasts by Type, 2016 – 2027 (Revenue, USD Million)
7.4.7. South Korea
7.4.7.1. Market estimates and forecasts by Agent, 2016 – 2027 (Revenue, USD Million)
7.4.7.2 Market estimates and forecasts by Type, 2016 – 2027 (Revenue, USD Million)
7.5. Latin America
7.5.1. Market estimates and forecasts by Agent, 2016 – 2027 (Revenue, USD Million)
7.5.2. Market estimates and forecasts by Type, 2016 – 2027 (Revenue, USD Million)
7.5.3. Brazil
7.5.3.1. Market estimates and forecasts by Agent, 2016 – 2027 (Revenue, USD Million)
7.5.3.2. Market estimates and forecasts by Type, 2016 – 2027 (Revenue, USD Million)
7.5.4 Mexico
7.5.4.1 Market estimates and forecasts by Agent, 2016 – 2027 (Revenue, USD Million)
7.5.4.2 Market estimates and forecasts by Type, 2016 – 2027 (Revenue, USD Million)
7.5.5 Argentina
7.5.5.1 Market estimates and forecasts by Agent, 2016 – 2027 (Revenue, USD Million)
7.5.5.2 Market estimates and forecasts by Type, 2016 – 2027 (Revenue, USD Million)
7.6 MEA
7.6.1 South Africa
7.6.1.1 Market estimates and forecasts by Agent, 2016 – 2027 (Revenue, USD Million)
7.6.1.2 Market estimates and forecasts by Type, 2016 – 2027 (Revenue, USD Million)
7.6.2 Saudi Arabia
7.6.2.1 Market estimates and forecasts by Agent, 2016 – 2027 (Revenue, USD Million)
7.6.2.2 Market estimates and forecasts by Type, 2016 – 2027 (Revenue, USD Million)
7.6.3 UAE
7.6.3.1 Market estimates and forecasts by Agent, 2016 – 2027 (Revenue, USD Million)
7.6.3.2 Market estimates and forecasts by Type, 2016 – 2027 (Revenue, USD Million)
Chapter 8 Competitive Landscape
8.1 Merz Pharma
8.1.1 Company overview
8.1.2 Financial performance
8.1.3 Product benchmarking
8.1.4 Recent developments
8.2 BTG
8.2.1 Company overview
8.2.2 Financial performance
8.2.3 Product benchmarking
8.2.4 Recent developments
8.3 Kreussler
8.3.1 Company overview
8.3.2 Financial performance
8.3.3 Product benchmarking
8.3.4 Recent developments
8.4 LGM Pharma
8.4.1 Company overview
8.4.2 Financial performance
8.4.3 Product benchmarking
8.4.4 Recent developments
8.5 Troikaa
8.5.1 Company overview
8.5.2 Product benchmarking
8.5.3 Product benchmarking
8.5.4 Recent developments
8.6 ChanganTianyu group
8.6.1 Company overview
8.6.2 Financial performance
8.6.3 Product benchmarking
8.6.4 Recent developments
8.7 Bioniche Pharma Group Ltd
8.7.1 Company overview
8.7.2 Financial performance
8.7.3 Product benchmarking
8.7.4 Recent developments
8.8 Omega Pharmaceuticals
8.8.1 Company overview
8.8.2 Financial performance
8.8.3 Product benchmarking
8.8.4 Recent developments
8.9 Endo-Flex
8.9.1 Company overview
8.9.2 Financial performance
8.9.3 Product benchmarking
8.9.4 Recent developments

List of Tables

Table 1 Country share estimation
Table 2 List of Abbreviation
Table 3 List of secondary sources

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Commodity flow analysis
Fig. 9 Volume Price Analysis
Fig. 10 Sclerotherapy market snapshot (2019)
Fig. 11 Sclerotherapy market segmentation
Fig. 12 Market driver relevance analysis (Current & future impact)
Fig. 13 Market restraint relevance analysis (Current & future impact)
Fig. 14 Penetration & growth prospect mapping
Fig. 15 Porter’s five forces analysis
Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 17 Sclerotherapy market Agent type outlook: Segment dashboard
Fig. 18 Sclerotherapy market: agent movement analysis
Fig. 19 Detergent market, 2016 - 2027 (USD Million)
Fig. 20 Chemical Irritants market, 2016 - 2027 (USD Million)
Fig. 21 Osmotic Agents market, 2016 - 2027 (USD Million)
Fig. 22 Sclerotherapy market Type outlook: Segment dashboard
Fig. 23 Sclerotherapy market: Type movement analysis
Fig. 24 Ultrasound Sclerotherapy market, 2016 - 2027 (USD Million)
Fig. 25 Liquid Sclerotherapy market, 2016 - 2027 (USD Million)
Fig. 26 Foam Sclerotherapy market, 2016 - 2027 (USD Million)
Fig. 27 Regional market: Key takeaways
Fig. 28 Regional outlook, 2019 & 2027
Fig. 29 North America market, 2016 - 2027 (USD Million)
Fig. 30 The U.S. market, 2016 - 2027 (USD Million)
Fig. 31 Canada market, 2016 - 2027 (USD Million)
Fig. 32 Europe market, 2016 - 2027 (USD Million)
Fig. 33 The U.K. market, 2016 - 2027 (USD Million)
Fig. 34 Germany market, 2016 - 2027 (USD Million)
Fig. 35 France market, 2016 - 2027 (USD Million)
Fig. 36 Italy market, 2016 - 2027 (USD Million)
Fig. 37 Spain market, 2016 - 2027 (USD Million)
Fig. 38 Asia Pacific market, 2016 - 2027 (USD Million)
Fig. 39 China market, 2016 - 2027 (USD Million)
Fig. 40 India market, 2016 - 2027 (USD Million)
Fig. 41 Japan market, 2016 - 2027 (USD Million)
Fig. 42 Australia market, 2016 - 2027 (USD Million)
Fig. 43 South Korea market, 2016 - 2027 (USD Million)
Fig. 44 Latin America market, 2016 - 2027 (USD Million)
Fig. 45 Brazil market, 2016 - 2027 (USD Million)
Fig. 46 Mexico market, 2016 - 2027 (USD Million)
Fig. 47 Argentina market, 2016 - 2027 (USD Million)
Fig. 48 MEA market, 2016 - 2027 (USD Million)
Fig. 49 South Africa market, 2016 - 2027 (USD Million)
Fig. 50 Saudi Arabia market, 2016 - 2027 (USD Million)
Fig. 51 UAE Market, 2016 - 2027 (USD Million)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[硬化療法の世界市場2020-2027:薬品別(洗剤、化学刺激剤、浸透剤)、種類別(超音波、液体、泡)、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆